Skip to main content

Table 1 Patients’ characteristics, risk factors for key distal lymph node metastasis in univariate analysis and multivariate analysis

From: Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy

Characteristics

Total

(N = 150)

Key distal lymph nodes negative

(N = 135)

Key distal lymph nodes positive

(N = 15)

p-value

(Univariate analysis)

Odd ratio and p-value

(Multivariate logistic regression analysis)

Sex (%)

Male

122 (81.3)

109 (80.7)

13 (86.7)

0.834

NA

Female

28 (18.7)

26 (19.3)

2 (13.3)

Age

 

61 [55.25,67]

61 [55,67]

61 [57,65]

0.728

NA

Tumor differentiation (%)

Well

7 (4.7)

7 (5.2)

0 (0.0)

0.02

Odd Ratio: 18.44;

p-value: 0.99

Moderately

41 (27.3)

41 (30.4)

0 (0.0)

Poorly

102 (68.0)

87 (64.4)

15 (100.0)

Tumor longitudinal diameter before chemotherapy

 

5.75 [4.62,8]

6 [5, 8]

5 [3, 8]

0.269

NA

Clinical T stage

T3

62(41.3)

61(45.2)

1(6.7)

0.009

Odd Ratio: 1.79;

p-value: 0.14

T4

88(58.7)

74(54.8)

14(93.3)

Clinical N stage

N0

10(6.7)

9(6.7)

1(6.7)

0.188

 

N1

59(39.3)

54(40.0)

5(33.3)

 

N2

71(47.3)

65(48.1)

6(40.0)

 

N3

10(6.7)

7(5.2)

3(20.0)

 

Neoadjuvant chemotherapy regimens

SOX

35(23.3)

32(23.7)

3(20.0)

0.09

NA

CAPOX

48(32.0)

45(33.3)

3(20.0)

Folfox

6(4.0)

5(3.7)

1(6.7)

mFLOT

43(28.7)

40(29.6)

3(20.0)

Others

18(12.0)

13(9.6)

5(33.3)

Cycles received before resection surgery

 

3 [3, 4]

3 [3, 4]

2 [2,3.50]

0.022

Odd Ratio: -0.06;

p-value: 0.85

Tumor longitudinal diameter after chemotherapy

 

3.50 [2.50,5]

3.50 [2.50,5]

4 [3, 7]

0.117

NA

R0 resection

 

143 (95.3)

128 (94.8)

15 (100.0)

0.796

 

Tumor regression grade* (%)

Grade 0

19 (12.7)

19 (14.1)

0 (0.0)

< 0.001

Odd Ratio: 1.47;

p-value: 0.04

Grade 1

22 (14.7)

21 (15.6)

1 (6.7)

Grade 2

81 (54.0)

79 (58.5)

2 (13.3)

Grade 3

28 (18.7)

16 (11.9)

12 (80.0)

ypT stage (%)

ypT0

19 (12.7)

18 (13.3)

0 (0.0)

0.033

Odd Ratio: 0.20;

p-value: 0.72

ypT1

11 (7.3)

11 (8.1)

0 (0.0)

ypT2

13 (8.7)

14 (10.4)

0 (0.0)

ypT3

89 (59.3)

79 (58.5)

10 (66.7)

ypT4

18 (12.0)

12 (8.9)

5 (33.3)

ypN stage (%)

ypN0

80(53.3)

80(59.3)

0(0.0)

< 0.001

Odd Ratio: 0.93;

p-value: 0.03

ypN1

27(18.0)

25(18.5)

2(13.3)

 

ypN2

18(12.0)

14(10.4)

4(26.7)

 

ypN3

25(16.7)

16(11.9)

9(60.0)

 

Number of total lymph node examined

 

37 [26.25,48.75]

37 [26,48]

44 [29.50,55]

0.163

NA

Adjuvant chemotherapy

SOX

32(21.3)

27(20.0)

5(33.3)

0.873

NA

CAPOX

48(32.0)

45(33.3)

3(20.0)

mFLOT

12(8.0)

12(8.9)

0(0.0)

Folfox

11(7.3)

10(7.4)

1(6.7)

Oral S-1

11(7.3)

10(7.4)

1(6.7)

Other

36(24.0)

31(23.0)

5(33.3)

Adjuvant cycles

 

3 [1, 4]

3 [1, 4]

2 [1, 3]

0.179

 

Number of total lymph node examined

 

37 [26.25,48.75]

37 [26,48]

44 [29.50,55]

0.163

NA

  1. Tumor regression grade: Grade 0 (pathological complete response); Grade 1 (major response); Grade 2 (minor response); Grade 3 (no response or progression)
  2. OR: odd ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us